Eli Lilly Japan, Daiichi Sankyo Ink Deal for Migraine Drug

Eli Lilly’s Japanese subsidiary and Daiichi Sankyo have finalized a deal to develop and commercialize Lilly’s migraine drug galcanezumab in Japan.

Under the agreement, Eli Lilly Japan will retain exclusive marketing rights while Daiichi Sankyo will handle distribution and sales following the approval of Lilly’s new drug application in Japan.

Galcanezumab is a monoclonal antibody that inhibits a peptide associated with migraines. The drug received FDA approval in 2018 and is used in 20 countries.